In autumn, the star investor Cathie Wood had put on biotech shares on a large scale. Now she pulled the ripcord again.
• Cathie Wood had recently heavily used biotech shares
• Commitment reduced at the end of March
• The reasons for the sales are unclear
Biotech companies had increased the interest of ARK boss Cathie Wood a few months ago. She had underpinned her growing confidence in the health sector with the purchase of STILLS of TEMPUS AI, Arcturus Therapeutics, Guardant Health and Intellia Therapeutics. But as part of a deposit adjustment, she reduced her commitment in the biotech sector last week.
Trading updates show sector reduction
Trading updates from last week make it clear that the investment company ARK Invest has reduced part of its biotech investments. On Wednesday, ARK sold 118,041 shares of repair therapeutics – title that are part of the ARK Genomic Revolution ETF. On Thursday, the investment company separated from a further 112,880 repairs therapeutic shares. This remained 1,126,962 repair shares in the portfolio on Friday. The deposit share fell to a manageable 0.12 percent, the participation is now still worth around $ 1.18 million.
There were also adjustments to the flagship fund Ark Innovation ETF (ARKK) in the biotech area on Thursday. This was a sales day for Illumina – 11,823 shares flew from the ARKK, another 2,577 shares were sold from the ARKG. The Ark flagship remained 659,203 Illumina title on Friday. With a total value of $ 52.74 million, they took a deposit share of 1.04 percent. In the Genomic Revolution ETF, Illumina shares remained on Friday 148.139, here the value of the shares that received a deposit share of 1.22 percent was $ 11.85 million.
Industry worries or custody cleansing?
It is unclear whether Cathie Wood’s recent sales from Cathie Wood in the biotechnology area suggest increasing skepticism in the industry. The star investor has not commented on whether her confidence in the health sector has cracked, the sales are due to strategic deposit adjustments or whether they even have company -specific reasons.
A wide range of industry skepticism speaks that Cathie Wood increased with an industry representative last week: 899,272 Shares of the biotechnology company Pacific Biosciences of California were added to the depot against the trend. Even in the days before, the Wood Group had already stocked up with shares of the biotech representative. With 21,467,376 shares in the ETF, the company was one of the 32 largest participations, the deposit share was 0.48 percent last Friday.
Editor finance.net
By the way: Guardant Health and other US shares are even tradable at Finance.net Zero until 11 p.m. (without order fees, plus spreads). Open Depot now for free And receive a free stock as a gift.
Selected leverage products on arcturus therapeutics
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we show you suitable open-end products on Arcturus Therapeutics
The lever must be between 2 and 20
Advertising
Image sources: Cindy Ord/Getty Images for Bloomberg Businessweek, Bluebay2014/Stock.adobe.com